Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
about
Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tractXenobiotic-metabolizing cytochrome P450 enzymes in the human feto-placental unit: role in intrauterine toxicityGeneration and analysis of mice with a targeted disruption of the arylamine N-acetyltransferase type 2 geneUroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(-/-) null mutant miceCharacterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and developmentToward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locusFor dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequentialMouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)Ahrd Cyp1a2(-/-) mice show increased susceptibility to PCB-induced developmental neurotoxicity.In utero and lactational exposure to PCBs in mice: adult offspring show altered learning and memory depending on Cyp1a2 and Ahr genotypesIdentification of novel stem cell markers using gap analysis of gene expression data.Hyper- and hypo-induction of cytochrome P450 activities with Aroclor 1254 and 3-methylcholanthrene in Cyp1a2(-/-) mice.Cytochrome P450-null mice.Regulation of cytochrome P450 (CYP) genes by nuclear receptors.Transcription coactivator peroxisome proliferator-activated receptor-binding protein/mediator 1 deficiency abrogates acetaminophen hepatotoxicityThe use of genetically altered animals in toxicology.The lung HETEs (and EETs) up.Using cytochrome P-450 gene knock-out mice to study chemical metabolism, toxicity, and carcinogenicity.Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer.In utero and lactational exposure to a complex mixture of polychlorinated biphenyls: toxicity in pups dependent on the Cyp1a2 and Ahr genotypes.Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models.Use of genetically engineered mice in drug discovery and development: wielding Occam's razor to prune the product portfolio.Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters.N-hydroxylation of 4-aminobiphenyl by CYP2E1 produces oxidative stress in a mouse model of chemically induced liver cancer.SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.Generation of 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-) mouse lineAromatic amines and biomarkers of human exposure.Activation of aflatoxin B1 by expression of human CYP1A2 polymorphisms in Saccharomyces cerevisiae.A metabolomic perspective of melatonin metabolism in the mouseThe role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis.Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor.Generation of a 'humanized' hCYP1A1_1A2_Cyp1a1/1a2(-/-)_Ahrd mouse line harboring the poor-affinity aryl hydrocarbon receptor.The role of the dioxin-responsive element cluster between the Cyp1a1 and Cyp1a2 loci in aryl hydrocarbon receptor biology.Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms.PhRMA white paper on ADME pharmacogenomics.Phenotype of the Cyp1a1/1a2/1b1-/- triple-knockout mouse.Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences--Cyp1 knockout mouse lines as a paradigm.Mitochondrial targeting of cytochrome P450 (CYP) 1B1 and its role in polycyclic aromatic hydrocarbon-induced mitochondrial dysfunction.
P2860
Q24643992-306E49FD-B9A4-4AFE-B6DD-2293E41C73E2Q28264076-9CBEF0DA-872A-4F6B-BA34-5FAF3F393EEEQ28506641-538A1EF7-81DA-4E07-90E6-D28C5252988EQ28506791-C2B9B765-FF5D-422D-9D07-2EB8CC84A8B3Q28507862-E6FFDE1A-5CDB-4D70-A0A4-91A85740086EQ28510807-7F01D9C9-74AA-4100-81FA-9B93415D4B0EQ28586157-90A9883D-DDED-4565-BF9D-45382731224AQ28592705-52FF9BE4-3BCD-42D0-817F-6AEA499867A6Q30446688-6389EBDD-1112-4F81-B058-67B13FC9121AQ30472131-674D91CC-F5AD-4CFB-821D-D2C3903A1C4CQ31129690-01AA94CC-9A93-4201-850F-BAF4BF3F19CDQ33609861-1107F9D5-64D6-4B75-8CCA-CF3977DD29E5Q33639766-CD0C6AD4-556F-4582-A1EE-314C590F3DEFQ33882753-3C3DD4CD-94D6-473D-B781-416627DD7CA4Q33920005-946653C4-E378-479D-A694-6793F6968A6FQ33947660-B351C16E-2060-411A-9C63-5512D1DDF99CQ34109234-F02DE102-0E71-496A-87E4-ABA75658254EQ34111582-DB8287AA-E249-4BDF-9AFA-DE8186605652Q34306783-07CA8B70-01D8-42CA-9989-C65664004E22Q34414579-55AD3B0E-085C-490B-B37B-EABDCA1A8EE8Q34513706-EACF7C4F-6C92-4597-BB12-247DC8BA2810Q34590536-2C81A055-600F-4B81-B938-381D3F194630Q35015993-617632A4-FA53-470B-B260-23FBE1A14552Q35166776-9B5D8CC4-DC18-4263-957C-B7110A5453F9Q35214609-2F8C46D2-D1BC-4F67-91E5-9E9DFAEE26A7Q35597098-FF9C729E-D6F3-4DB5-8401-573D5833ACD0Q36014555-B026935A-AACA-4B4F-9708-2355B1FF897CQ36104064-537C9BE9-AC55-4DC4-8B43-CE7DD97E898EQ36450003-4B1195FB-0BFE-4298-92EF-7608B4E85C64Q36513111-D8A326F5-0AE4-433F-B39C-A0D2EF30321AQ36664974-3392D9AC-C33C-44CD-A1A0-19AE0F151200Q36927028-5EB1C9BF-BEBA-4076-96E2-9D5934179AAAQ36972826-0D3B778F-719C-4205-AB94-2FF4DCEA5959Q37117413-FF230A43-D56F-4839-82BE-6378BE54036CQ37157901-5B64854A-2842-41CC-9FBC-9075E5D44018Q37182212-2F12A73B-283C-4917-961A-4B4398D9017DQ37327492-E3810DF2-35D6-4FBB-A60D-8A40BA4CD7C1Q37378059-EDE7A358-C937-4E9F-B0B7-3CD014F5F9BEQ37422752-7F00E52A-2B86-4BFC-8DF4-E7C41118004EQ37683416-C12F3ADE-8E61-41E4-A0B3-504AF66D44DF
P2860
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
description
1996 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
article publié dans les Procee ...... f the United States of America
@fr
artículu científicu espublizáu en 1996
@ast
im Februar 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1996/02/20)
@sk
vědecký článek publikovaný v roce 1996
@cs
wetenschappelijk artikel (gepubliceerd op 1996/02/20)
@nl
наукова стаття, опублікована в лютому 1996
@uk
name
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@ast
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@en
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@nl
type
label
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@ast
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@en
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@nl
prefLabel
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@ast
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@en
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@nl
P2093
P2860
P356
P1476
Cyp1a2(-/-) null mutant mice develop normally but show deficient drug metabolism
@en
P2093
P2860
P304
P356
10.1073/PNAS.93.4.1671
P407
P577
1996-02-01T00:00:00Z